69P TGFBI promoter methylation validation as an epigenetic biomarker for trastuzumab resistance in HER2+ breast cancer patients cohort

Helena Pla; Ángel Díaz‐Lagares; A. Hernández; Glòria Oliveras; Ferran Pérez-Bueno; Manel Esteller; Teresa Puig; Sònia Palomeras; Gemma Viñas

doi:10.1016/j.annonc.2020.03.203

Related publications

Article2019

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

Sònia Palomeras, Ángel Díaz‐Lagares, Gemma Viñas, Fernando Setién, Humberto J. Ferreira, Glòria Oliveras, Ana B. Crujeiras, A. Hernández, David H. Lum, Alana L. Welm, Manel Esteller, Teresa Puig

Article2017

DNA methylation signature to identify trastuzumab response in HER2 breast cancer models

Sònia Palomeras, Ángel Diaz Lagares, Adriana Blancafort, Ariadna Sarrats, A.B. Crujeiras Martinez, Juan Sandoval, Marc Rabionet, Alana L. Welm, Manel Esteller, Teresa Puig

Article2016

Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models

Sònia Palomeras Pairet, Ángel Diaz Lagares, Ariadna Sarrats Carbó, Ana-Belen Crujeiras, Ariadna Giró Perafita, Juan Sandoval, Mariona Rabionet, Manel Esteller, Teresa Puig

Article2016

Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models

Sònia Palomeras Pairet, Ángel Diaz Lagares, Ariadna Sarrats Carbó, Ana-Belen Crujeiras, Ariadna Giró Perafita, Juan Sandoval, Mariona Rabionet, Manel Esteller, Teresa Puig

Article2016

Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models

Sònia Palomeras, Ángel Díaz‐Lagares, Ariadna Sarrats, Crujeiras Ana Belen, Ariadna Giró‐Perafita, Juan Sandoval, Marc Rabionet, Manel Esteller, Teresa Puig

69P TGFBI promoter methylation validation as an epigenetic biomarker for trastuzumab resistance in HER2+ breast cancer patients cohort

Discussion(0)

Related publications

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

DNA methylation signature to identify trastuzumab response in HER2 breast cancer models

Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models

Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models

Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models